What is the standard adult dosing for ketorolac (Toradol) by oral, intravenous, and intramuscular routes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Standard Adult Dosing for Ketorolac (Toradol)

For adult patients, ketorolac should be dosed at 15-30 mg IV/IM every 6 hours (maximum 120 mg/day for patients <65 years, 60 mg/day for patients ≥65 years), with treatment duration not exceeding 5 days combined IV/IM/oral therapy. 1

Route-Specific Dosing

Intravenous (IV) Administration

Single-Dose Regimen:

  • Patients <65 years: 30 mg IV bolus over ≥15 seconds
  • Patients ≥65 years, renally impaired, or <50 kg: 15 mg IV bolus over ≥15 seconds 1

Multiple-Dose Regimen:

  • Patients <65 years: 30 mg IV every 6 hours (maximum 120 mg/day)
  • Patients ≥65 years, renally impaired, or <50 kg: 15 mg IV every 6 hours (maximum 60 mg/day) 1

Intramuscular (IM) Administration

Single-Dose Regimen:

  • Patients <65 years: 60 mg IM (deep, slow injection)
  • Patients ≥65 years, renally impaired, or <50 kg: 30 mg IM 1

Multiple-Dose Regimen:

  • Patients <65 years: 30 mg IM every 6 hours (maximum 120 mg/day)
  • Patients ≥65 years, renally impaired, or <50 kg: 15 mg IM every 6 hours (maximum 60 mg/day) 1

Oral Administration

Oral ketorolac is ONLY indicated as continuation therapy following IV/IM dosing—never as initial treatment. The typical oral dose is 10 mg every 4-6 hours as needed, but this must be part of the combined 5-day maximum treatment duration. 1

Critical Dosing Considerations

The Analgesic Ceiling Effect

Recent high-quality evidence demonstrates that lower doses of ketorolac (10-15 mg IV) provide equivalent analgesia to higher doses (30 mg IV) with potentially fewer adverse effects. A 2017 randomized controlled trial of 240 ED patients showed no difference in pain reduction at 30 minutes between 10 mg, 15 mg, and 30 mg IV doses (mean difference 0.2-0.3 points on 0-10 scale). 2 A 2023 systematic review confirmed that low-dose ketorolac (10-20 mg) is probably as effective as high-dose (≥30 mg) for acute pain relief. 3

However, the FDA-approved dosing remains 30 mg IV for patients <65 years, and this should guide practice until official labeling changes. 1 The evidence suggests you can safely use lower doses (15 mg IV) if concerned about adverse effects, particularly in vulnerable populations.

Duration Limits Are Absolute

The 5-day maximum duration applies to ALL routes combined (IV + IM + oral). This is non-negotiable due to increased risk of serious gastrointestinal bleeding, renal toxicity, and cardiovascular events with prolonged use. 1 Patients must be transitioned to alternative analgesics before reaching this limit.

Age-Based Dose Reduction

Elderly patients (≥65 years) have prolonged ketorolac half-life (7 hours vs. 5 hours in younger adults) and require 50% dose reduction. 1 This is based on pharmacokinetic data showing decreased clearance without significant changes in peak concentrations. 4

Weight and Renal Function Adjustments

Patients <50 kg (110 lbs) or with any degree of renal impairment require the same dose reduction as elderly patients (15 mg IV every 6 hours, maximum 60 mg/day). 1 Ketorolac clearance is poorly correlated with creatinine clearance in renal disease, and the AUC doubles in renally impaired patients. 1

Common Pitfalls to Avoid

  1. Do not mix ketorolac in a syringe with morphine, meperidine, promethazine, or hydroxyzine—this causes precipitation. 1

  2. Correct hypovolemia before administering ketorolac to minimize renal toxicity risk. 1

  3. Do not exceed 5 days total therapy even if switching between routes—this is when serious adverse events increase substantially.

  4. Recognize that most emergency departments historically overdose ketorolac: A 2017 observational study found 97% of IV doses and 96% of IM doses exceeded the analgesic ceiling dose. 5 While FDA dosing remains the standard, evidence supports that 15 mg IV is equally effective with potentially better safety.

  5. For breakthrough pain, do not increase ketorolac dose or frequency—instead, add low-dose opioids as rescue analgesia if not contraindicated. 1

Onset and Duration of Action

Analgesic effect begins in approximately 30 minutes with maximum effect at 1-2 hours after IV or IM administration. Duration of analgesia is typically 4-6 hours, which aligns with the every-6-hour dosing interval. 1

Related Questions

What is the recommended intramuscular dosing of ketorolac (Toradol) for adults, including adjustments for patients aged 65 years or older or with impaired renal function?
Can ketorolac (Toradol) be given to a patient presenting with chest pain?
Is ketorolac tromethamine the standard injectable analgesic used in outpatient clinics?
Can the patient who received a ketorolac (Toradol) injection today be continued on oral ketorolac (Toradol) and what is the appropriate dosing?
What is the recommended dosage and safety considerations for ketorolac (Toradol) in a healthy 21‑year‑old female?
What pathologic feature favors ANCA-associated glomerulonephritis over IgA nephropathy?
What broad‑spectrum IV antibiotic regimen is recommended for gastric perforation, including alternatives for β‑lactam allergy and appropriate duration of therapy?
I have been off Latuda (lurasidone) for 21 days; when can I expect to feel better?
What is the current evidence for using B‑cell‑depleting therapy (rituximab) in adults with biopsy‑proven IgA nephropathy who have persistent proteinuria ≥1 g/day despite maximally tolerated angiotensin‑converting enzyme inhibitor or angiotensin receptor blocker therapy?
In a patient with a pontine infarct presenting with headache, left upper‑limb sensory loss and posterior neck numbness, is this a lacunar infarct of the anterior circulation (LACI), a partial anterior‑circulation infarct (PACI), or another type of stroke?
Can losartan be used in a patient with chronic kidney disease stage 3 (estimated GFR 30‑59 mL/min/1.73 m²)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.